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1. INTRODUCTION {#cam42488-sec-0001}
===============

Breast cancer is the malignant tumor most commonly diagnosed in women in North America and Europe, with approximately 1 151 000 new cases per year (22.7% of all cancer cases among the female population)[1](#cam42488-bib-0001){ref-type="ref"} and the most prevalent tumor worldwide for 5 years, among both sexes (19.2%). In Spain, the GLOBOCAN 2012 report estimated that the overall incidence of breast cancer was 27 182 cases in 2012. Among women, this tumor presented the highest incidence, mortality, and prevalence for 5 years (29%, 15.5%, and 40.8%, respectively).[2](#cam42488-bib-0002){ref-type="ref"} Though the mortality from breast cancer increased sharply from 1950s to 1980s,[3](#cam42488-bib-0003){ref-type="ref"} in most developed countries it has fallen in the last two decades, due to the success of new treatments and the implementation of screening programs[4](#cam42488-bib-0004){ref-type="ref"}.

The breast cancer tumors detected by the screening generally have a good prognosis, due to the existence of biological differences associated with reduced aggressiveness and better survival compared to symptomatic tumors, such as positivity for the expression of hormonal receptors and a lower rate of cellular proliferation.[5](#cam42488-bib-0005){ref-type="ref"}, [6](#cam42488-bib-0006){ref-type="ref"}

However, this better prognosis is also due to associated biases such as selection bias, lead‐time bias, duration bias, and possibly overdiagnosis bias.[7](#cam42488-bib-0007){ref-type="ref"}, [8](#cam42488-bib-0008){ref-type="ref"}

Cancer patients often present associated comorbidities, which are known to influence the disease prognosis and to limit the possibilities for the oncological treatment. The Charlson comorbidity index (CCI), a prognostic index that has been validated for the use in various populations, classifies and scores 19 patient‐associated diseases, and has been proposed as an indicator of the probability of 10‐year survival.[9](#cam42488-bib-0009){ref-type="ref"}

The administration of adjuvant chemotherapy (ACh) has been shown to increase the survival in localized breast cancer with clinical risk features such as axillary involvement, large tumor size, the presence of a triple‐negative phenotype or HER2‐enriched subtype, or classification as a tumor with high risk of recurrence according to a genetic platform.[10](#cam42488-bib-0010){ref-type="ref"}, [11](#cam42488-bib-0011){ref-type="ref"} However, some tumors present intermediate genetic risk, or have a less aggressive immunohistochemical profile, and these are less likely to benefit from the ACh treatment, which inevitably provokes a deterioration in the patient\'s quality of life. Some patients who fit this profile are identified in early‐detection programs. In view of the good prognosis associated with the majority of breast cancers diagnosed by screening, we consider it of interest to include this diagnostic factor in the decision‐making process. Accordingly, this study analyses the survival benefit of ACh in each of the patient\'s groups diagnosed by screening, taking observed comorbidity into account.

2. MATERIALS AND METHODS {#cam42488-sec-0002}
========================

In breast cancer diagnosed by screening, three groups of patients can be distinguished: Prevalent cancer, diagnosed in the first round, with an apparently better prognosis; incident cancer, diagnosed in subsequent rounds; and interval cancer, detected between one round and the next, by clinical indications.

2.1. Study design {#cam42488-sec-0003}
-----------------

This multicenter retrospective cohort study was conducted to identify and classify the breast cancers detected by the mammographic screening as prevalent, incident, or interval tumor.

2.2. Study population {#cam42488-sec-0004}
---------------------

This study included 1248 women aged 45‐69 years who had taken part in four national breast‐cancer screening programs, providing biannual mammograms and annual examinations for women with clinical indications of increased risk. They were healthy women and initially without known risk factors for breast cancer. The hospitals involved were all in Spain----in the Costa del Sol (Marbella), the Canary Islands, Sabadell, and Gerona----and the diagnoses and surgical interventions all took place during the period 2000‐2008, with follow‐up to 2014. The women in the study population were mainly derived from the retrospective cohort of the CAMISS study (n = 1086) and the rest had been diagnosed within the screening program provided at the Costa del Sol Hospital, Marbella.[12](#cam42488-bib-0012){ref-type="ref"}

The following inclusion criteria were applied: Anatomic‐pathological diagnosis of infiltrating breast cancer.Localized or locally advanced stage.Age 50‐69 years.

These exclusion criteria were applied: The presence of lymphoma, sarcoma, or inflammatory carcinoma.Cancer not unresectable.Patients who had not received prior chemotherapy, due to associated comorbidity.

2.3. Ethical issues {#cam42488-sec-0005}
-------------------

The study was performed in accordance with the good clinical practice guidelines of the Helsinki Declaration. Informed consent was obtained from all patients to take part in the study and for their clinical records to be reviewed. This project was approved by the ethics review board of each of the participating centers.

2.4. Variables {#cam42488-sec-0006}
--------------

The following variables were obtained from the patients' clinical record.

Main study variable (dependent): Variables related to survival (recurrence, metastasis, and death).

Independent variables: Treatment: Neoadjuvant: radiotherapy (and date performed); chemotherapy----schedule, number of cycles, and date performed; molecular therapy and date performed; hormonal systemic treatment, and date performed. Adjuvant: reintervention; systemic hormonal treatment and date performed; radiotherapy and chemotherapy, and date performed----schedule, number of cycles, and date performed; molecular therapy and date performed; consultation with rehabilitation; contralateral prophylactic mastectomy; plastic reconstruction; prevention and treatment of treatment complications such as lymphedema or bone loss.Patient\'s clinical history: surgical interventions; patient‐associated diseases, required to calculate the CCI, namely myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic lung disease, connective tissue pathology, ulcerative disease, mild, moderate or severe hepatic disease, diabetes, diabetes with organic lesion, hemiplegia, renal pathology (moderate or severe), solid neoplasms, leukaemia, malignant lymphoma, solid metastasis, and/or AIDS.[9](#cam42488-bib-0009){ref-type="ref"}

Adjustment variables: Patients: age, family history, and menopause.Hospital care: the time between diagnosis and first treatment.Surgical intervention: date, type of surgical technique (conservative or radical, lymphadenectomy or selective sentinel lymph node biopsy).Tumor screening characteristics: those diagnosed in the first round, prevalent; those diagnosed in subsequent rounds, incident; those detected between one round and another, interval; classified by clinical signs, histological type, degree of differentiation, location, size, presence and location of distant metastasis, vascular/nervous infiltration, hormonal receptors, expression of c‐ERB‐b2, number of lymph nodes analyzed, number of positive lymph nodes, involvement of margins, cTNM, pTNM, p53, Ki67, apoptotic index, and selective sentinel lymph node biopsy. The tumors are classified into four immunophenotypes according to the expression of hormone receptors and HER2: Luminal A, Luminal B, HER2+, and TNBC.Clinical follow‐up: readmission, recurrence (yes/no, type, and date), treatment complications, status at the end of follow‐up, and death (yes/no, date, and cause).

2.5. Statistical analysis {#cam42488-sec-0007}
-------------------------

### 2.5.1. Univariate analysis {#cam42488-sec-0008}

Descriptive analysis segmented by the types of breast cancer. Comparison of frequencies between two variables (clinical‐pathological and molecular) by the chi‐square test when appropriate, otherwise (if results \<5 expected in \>20% of cases) by the Fisher\'s test. Comparison of the means by the Student\'s *t* test, after confirming the normal distribution of the quantitative variable and the homogeneity of the variance. If these conditions were not met, the variable was transformed or nonparametric tests were performed.

### 2.5.2. Multivariate analysis {#cam42488-sec-0009}

Cox regression analysis, crude and multivariate, was applied to estimate the risk of recurrence and death. The multivariate analysis was adjusted with entry criteria for the following variables: chemotherapy group (with or without ACh), stage, and comorbidity according to the CCI.

To preserve the statistical power in the multivariate analysis, and since it is an explanatory model, we decided to discard those variables that had a high number of losses (Ki 67 expression), that could be correlated with other variables (comorbidity, estrogen and progesterone receptors, and Her2 expression) or directly did not contribute to the model in the crude analysis (age). The relative risk and the corresponding 95% CI were calculated. In the survival study, the primary endpoint was time elapsed until local recurrence, distance, or death from breast cancer, from the time of diagnosis. Survival times for patients who were still alive or who died from other causes were centered at the date of the last follow‐up. For the Cox regression analysis of the risk of recurrence and death, crude and multivariate analyses were performed (columns 1 and 2, Table [2](#cam42488-tbl-0002){ref-type="table"}). The sample sizes for these analyses were somewhat lower, 1028 and 1024, respectively, due to losses to follow‐up.

3. RESULTS {#cam42488-sec-0010}
==========

Studied data were analyzed for 1248 women aged 45‐69 years, most of whom (n = 1086) formed part of the retrospective cohort of the CAMISS study. Of this population, 45.6% had received adjuvant chemotherapy, 10% neoadjuvant chemotherapy, and 75.7% hormone therapy. Table [1](#cam42488-tbl-0001){ref-type="table"} shows the differences in the distribution of clinical‐biological characteristics between the three groups that received breast cancer screening. In the interval group, 25.7% of the patients presented stage III. The corresponding values for the incident and prevalent groups were 6.8% and 5.8% (*P* \< .001), respectively.

###### 

Distribution of frequencies, by screening groups

                              Prevalent      Incidence      Interval       
  --------------------------- -------------- -------------- -------------- ---------
  Stage                                                                    
  IN SITU                     37 (14.3)      70 (11.3)      14 (4.2)       \<0.001
  I                           139 (53.7)     345 (55.6)     89 (26.6)      
  II                          68 (26.3)      164 (26.4)     145 (43.4)     
  III                         15 (5.8)       42 (6.8)       86 (25.7)      
  Unknown                     7              12             15             
  Mean age (min‐max)          55.6 (49‐70)   60.1 (48‐70)   57.7 (49‐71)   \<0.001
  Phenotype                                                                
  Luminal A                   60 (48.8)      218 (52.5)     140 (45.5)     \<0.001
  Luminal B                   49 (39.8)      131 (31.6)     84 (27.3)      
  HER2                        12 (9.8)       28 (6.7)       34 (11)        
  Triple negative             2 (1.6)        38 (9.2)       50 (16.2)      
  Unknown                     143            218            41             
  Comorbidity                                                              
  Absent                      147 (78.2)     387 (70)       254 (73.6)     0.081
  Present                     41 (21.8)      166 (30)       91 (26.4)      
  Unknown                     78             80             4              
  CCI (min‐max)               0.62 (0‐9)     0.81 (0‐13)    0.79 (0‐7)     0.367
  Oestrogen receptors                                                      
  Negative                    41 (16.1)      100 (16.1)     97 (27.8)      \<0.001
  Positive                    213 (83.9)     520 (83.9)     252 (72.2)     
  Unknown                     12             13             0              
  Progesterone receptors                                                   
  Negative                    67 (26.4)      199 (32.1)     147 (42.2)     \<0.001
  Positive                    187 (73.6)     420 (67.9)     201 (57.8)     
  Unknown                     12             14             1              
  Her2                                                                     
  Negative                    108 (80.6)     357 (80.6)     245 (77.5)     0.557
  Positive                    26 (19.4)      86 (19.4)      71 (22.5)      
  Unknown                     132            190            33             
  ki67 expression                                                          
  ≤14%                        77 (62.1)      124 (51.9)     110 (53.7)     0.166
  \>14%                       47 (37.9)      115 (48.1)     95 (46.3)      
  Unknown                     142            394            144            
  Type of histology                                                        
  Ductal infiltrating         195 (73.9)     456 (72)       258 (75.2)     \<0.001
  Ductal in situ              35 (13.3)      61 (9.6)       12 (3.5)       
  Lobular                     23 (8.7)       71 (11.2)      38 (11.1)      
  Other                       11 (4.2)       45 (7.1)       35 (10.2)      
  Unknown                     2              0              6              
  Family history                                                           
  Yes                         19 (12.6)      67 (14.8)      21 (9.5)       0.164
  No                          132 (87.4)     387 (85.2)     201 (90.5)     
  Unknown                     115            179            127            
  Degree of differentiation                                                
  Category I                  48 (34.8)      135 (30)       51 (17.9)      \<0.001
  Category II                 62 (44.9)      190 (42.2)     107 (37.5)     
  Category III                28 (20.3)      125 (27.8)     127 (44.6)     
  Unknown                     128            183            64             
  Recurrence                                                               
  No                          244 (92.1)     566 (89.6)     272 (77.9)     \<0.001
  Yes                         21 (7.9)       66 (10.4)      77 (22.1)      
  Death                                                                    
  No                          245 (92.1)     570 (90)       272 (77.9)     \<0.001
  Yes                         21 (7.9)       63 (10)        77 (22.1)      
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No significant differences were detected among the three groups in terms of the distribution of comorbidity according to the CCI. After a median follow‐up of 102 months, 22.1% of the interval group, 10.4% of the incident group, and 7.9% of the prevalent group had died (*P* \< .001).

The multivariate Cox regression analysis showed that the comorbidity variables according to the CCI, the triple‐negative phenotype, HER2‐enriched subtype, and Stage III were all associated with a higher risk of recurrence and death. However, no such association was observed for an increased histological grade (see Table [2](#cam42488-tbl-0002){ref-type="table"}).

For the independent principal variable (ACh: yes/no), differences in the proportion of recurrences were observed, but without reaching the statistical significance. However, there were significant differences in overall survival, with a higher risk of death for the interval group without ACh: hazard rate 2.5 (1.0‐6.2) with respect to the other groups. However, for the patients with prevalent or incident cancer who did not receive ACh, there was no greater risk of death. Figures [1](#cam42488-fig-0001){ref-type="fig"} and [2](#cam42488-fig-0002){ref-type="fig"} illustrate the analyses of recurrence‐free survival and overall survival, for each of the patient\'s groups diagnosed by screening.

![Disease‐free survival of breast cancer patients according to the groups of screening](CAM4-8-6662-g001){#cam42488-fig-0001}

![Overall survival according to groups of screening](CAM4-8-6662-g002){#cam42488-fig-0002}

###### 

Cox regression analysis adjusted for ACh, Stage, and Charlson comorbidity index (CCI)

                                 Recurrence         Death                              
  ------------------------------ ------------------ --------------- ------------------ ----------------
  Group                                                                                
  Prevalent                      Ref.               ---             Ref.               ---
  Incident                       1.4 (0.9‐2.4)      ---             1.4 (0.9‐2.3)      ---
  Interval                       3.3 (2.0‐5.3)      ---             3.5 (2.1‐5.7)      ---
  Group + Ach                                                                          
  Prevalent, no chemotherapy     Ref.               Ref.            Ref.               Ref.
  Prevalent, with chemotherapy   2.4 (0.9‐6.0)      1,2 (0,4‐3,4)   1.9 (0.7‐4.6)      1,2 (0,4‐3,3)
  Incident, with chemotherapy    3.1 (1.4‐7.0)      1,4 (0,6‐3,6)   2.5 (1.1‐5.4)      1,5 (0,6‐3,6)
  Incident no chemotherapy       1.9 (0.8‐4.3)      1,4 (0,6‐3,6)   1.7 (0.8‐3.7)      1,4 (0,6‐3,2)
  Interval, with chemotherapy    5.0 (2.3‐11.2)     1,9 (0,8‐4,9)   4.5 (2.1‐9.7)      2,1 (0,9‐5,1)
  Interval, no chemotherapy      6.4 (2.9‐14.6)     2,2 (0,9‐5,7)   6.1 (2.8‐13.3)     2,5 (1,0 −6,2)
  Age                                                                                  
                                 1.01 (0.98‐1.04)   ---             1.02 (0.99‐1.05)   ---
  Comorbidity                                                                          
  Absent                         Ref.               ---             Ref.               ---
  Present                        1.1 (0.78‐1.56)    ---             1.43 (1.03‐1.99)   ---
  CCI                                                                                  
                                 1.0 (0.93‐1.13)    1.1 (0.9‐1.2)   1.1 (1.01‐1.20)    1.1 (1‐1.2)
  Phenotype                                                                            
  Luminal A                      Ref.               Ref.            Ref.               Ref.
  Luminal B                      1.2 (0.8‐1.9)                      1.0 (0.6‐1.6)       
  Her2                           3.2 (1.9‐5.3)                      2.8 (1.7‐4.6)       
  Triple negative                2.2 (1.3‐3.7)                      2.0 (1.2‐3.4)       
  Stage                                                                                
  I                              Ref.               Ref.            Ref.               Ref.
  IN SITU                        0.3 (0.1‐1.0)      0,2 (0,1‐1)     0.2 (0.0‐0.8)      0,2 (0,1‐0,9)
  II                             1.4 (1.0‐2.2)      1,1 (0,7‐1,8)   1.2 (0.8‐1.8)      0,9 (0,6‐1,5)
  III                            5.5 (3.7‐8.1)      4,3 (2,7‐6,9)   4.3 (2.9‐6.4)      3,1 (2,0‐4,9)
  IV                             ---                                ---                 
  Oestrogen receptors                                                                  
  Negative                       Ref.               ---             Ref.               ---
  Positive                       0.6 (0.4‐0.8)      ---             0.5 (0.4‐0.8)      ---
  Progesterone receptors                                                               
  Negative                       Ref.               ---             Ref.               ---
  Positive                       0.6 (0.4‐0.8)      ---             0.6 (0.4‐0.8)      ---
  Her 2                                                                                
  Negative                       Ref.               ---             Ref.               ---
  Positive                       1.7 (1.2‐2.5)      ---             1.6 (1.1‐2.3)      ---
  Ki67 expression                                                                      
  ≤14%                           Ref.               ---             Ref.               ---
  \>14%                          1.9 (1.2‐3.0)      ---             1.9 (1.2‐3.1)      ---
  Grade                                                                                
  I                              Ref.               ---             Ref.               ---
  II                             2.1 (1.2‐3.7)      ---             1.9 (1.1‐3.1)      ---
  III                            3.1 (1.8‐5.4)      ---             2.5 (1.5‐4.1)      ---
  Other                          0.7 (0.2‐2.4)      ---             0.6 (0.2‐1.9)      ---

Sample evaluated: recurrence n = 1.028, Sample evaluated: death n = 1.024.

Cox regression analysis adjusted for ACh, Stage, and Charlson comorbidity Index.
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4. DISCUSSION {#cam42488-sec-0011}
=============

Screening for breast cancer facilitates detection at an early stage of the disease. Moreover, it is well established that breast cancers detected by screening have a better prognosis, even after adjusting for the stage of the disease.[5](#cam42488-bib-0005){ref-type="ref"}, [9](#cam42488-bib-0009){ref-type="ref"}, [13](#cam42488-bib-0013){ref-type="ref"} In general, these cancers present less aggressive clinical‐pathological and molecular characteristics than those observed in nonscreening or symptomatic patients.[6](#cam42488-bib-0006){ref-type="ref"}, [14](#cam42488-bib-0014){ref-type="ref"}, [15](#cam42488-bib-0015){ref-type="ref"}, [16](#cam42488-bib-0016){ref-type="ref"} Moreover, differences have also been reported among patients diagnosed during a screening program; patients with interval breast cancer have the poorest prognosis, equal to that of symptomatic patients, due to the larger size of the tumor, the low degree of differentiation, and the presence of lymph node involvement. However, not all studies are in agreement on this question.[17](#cam42488-bib-0017){ref-type="ref"}

However, the use of screening (based on mammography) and the corresponding subgroup (prevalent, incident or interval cancer) is not generally taken into account in stratifying the risk of recurrence and in deciding on the treatment to be provided. In the present study, and unlike previous approaches in this field, classification according to these three subgroups was performed for a large sample of patients, taking part in national public screening programs. Significant differences were observed in the distribution of prognostic factors, with a higher percentage of advanced stages, poorly differentiated, and an absence of hormonal receptors among the patients with interval cancer, followed in frequency by patients with incident and prevalent cancer, respectively. This finding is consistent with and complements the results obtained in a previous pilot study in this respect, in which the tumors diagnosed in the first round presented less aggressive pathological characteristics than those observed among patients with incident cancer.[6](#cam42488-bib-0006){ref-type="ref"}, [18](#cam42488-bib-0018){ref-type="ref"}

According to previous studies of patients presenting negative results for the expression of hormone receptors, Stages III, grade III histological differentiation and Ki 67 index \>14% were positively associated with the likelihood of recurrence and death. A similar association was observed for HER‐2 positive tumors, because adjuvant therapy with trastuzumab, the monoclonal antibody against the HER‐2 receptor, was not yet approved. This treatment option is known to improve the prognosis for this histological subtype.[19](#cam42488-bib-0019){ref-type="ref"}, [20](#cam42488-bib-0020){ref-type="ref"}

An unavoidable area of bias in our results is the loss of follow‐up for some patients for the analysis of recurrence and death, though this situation only affected a small number of patients.

The patients with incident cancer were at greater risk of recurrence and mortality when the chemotherapy was administered, though the difference disappeared when the stage of the disease and the associated comorbidity were taken into account. Moreover, the presence of interval cancer was associated with poorer rates of survival, especially in the absence of complementary chemotherapy. However, some studies have disputed this conclusion, finding that patients with interval breast cancer diagnosed within 24 months of negative mammographic screening have better survival rates than those diagnosed with no such screening.[21](#cam42488-bib-0021){ref-type="ref"}, [22](#cam42488-bib-0022){ref-type="ref"}

Comorbidity is a recognized prognostic factor for various tumors and should be taken into account. Moreover, the CCI is a reliable system for evaluating survival, and our study highlights its utility as an independent predictor of mortality in patients with breast cancer diagnosed by screening.[23](#cam42488-bib-0023){ref-type="ref"}, [24](#cam42488-bib-0024){ref-type="ref"} Despite these benefits, few previous studies have included this instrument in their evaluation of treatment strategies, and none have examined the influence of ACh in breast cancer tumors identified in national screening programs. One of the main strengths of our study, and hence of the conclusions drawn, is that the survival analysis was adjusted not only for the stage of the disease but also for comorbidity, as determined by the CCI.

Adjuvant chemotherapy has been shown to reduce the probability of recurrence and morbi‐mortality in patients with localized breast cancer. However, when the prognosis is good, this benefit is often minimal and the treatment is not free of side effects, and therefore, clinical or genetic platform is often used to determine the risk of recurrence and to decide whether or not to administer ACh.[25](#cam42488-bib-0025){ref-type="ref"} To derive a recurrence score for this purpose, these methods combine the classical characteristics of clinical prognosis with the genetic information about the tumor. However, they do not include the information on which the diagnosis was based, which as we see appears to have an independent prognostic value.[26](#cam42488-bib-0026){ref-type="ref"} This omission could lead to the benefits of systemic treatments being overestimated for the population taking part in the screening program.[8](#cam42488-bib-0008){ref-type="ref"}

In view of these considerations, and having found that the patients with interval breast cancer without the adjuvant treatment have poorer survival rates than the other groups, and that the administration of chemotherapy did not influence the survival of patients with prevalent or incident tumor, we emphasize the importance of considering not only comorbidity but also the origin of the data obtained (ie, from a screening program), when making decisions in usual clinical practice.
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